3-<2-(Hydroxy-aethyl)>-tetrahydro-thiophen-1,1-dioxid | 89791-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 3-<2-(Hydroxy-aethyl)>-tetrahydro-thiophen-1,1-dioxid
• 英文别名: 2-(1,1-Dioxidotetrahydro-3-thienyl)ethanol；2-(1,1-dioxothiolan-3-yl)ethanol
• CAS: 89791-51-5
• 化学式: C₆H₁₂O₃S
• mdl: MFCD11099935
• 分子量: 164.225
• InChiKey: VTZBGOGKRKZJJY-UHFFFAOYSA-N

物化性质

• 沸点：
  185 °C(Press: 7-8 Torr)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Inhibitors of JNK
  申请人：Gong Leyi

  公开号：US20110301170A1

  公开（公告）日：2011-12-08

  Compounds of formula I or pharmaceutically acceptable salts thereof, wherein: wherein m, n, p, q, X Y, Z, A, R 1 , R 2 , R 3 , R 4 , R 5 and Y 6 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.

  公式I的化合物或其药用盐，其中：其中m、n、p、q、X、Y、Z、A、R1、R2、R3、R4、R5和Y6如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。
• Quinazoline derivatives as antitumor agents
  申请人：Hennequin Francois Andre Laurent

  公开号：US20050043336A1

  公开（公告）日：2005-02-24

  The invention concerns quinazoline derivatives of Formula (I); wherein each of Q 1 , Q 2 , Z, R 1 , R 2 , R 3 , and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosin kinases.

  该发明涉及公式（I）的喹唑啉衍生物；其中Q1，Q2，Z，R1，R2，R3和m的每个定义在说明中具有任何意义；它们的制备过程，包含它们的制药组合物以及它们在制造对erbB受体酪氨酸激酶抑制敏感的肿瘤的预防或治疗药物中的使用。
• ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON
  申请人：Shionogi Co., Ltd.

  公开号：EP1887000A1

  公开（公告）日：2008-02-13

  A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y is not optionally substituted phenyl which is substituted with the formula: -CR9R10X3 at the para position, R1 to R10 are each independently halogen, hydroxy, optionally substituted lower alkyl, optionally substituted aryl or the like, X1 is -O-, -S- or the like.

  式 (I) 的化合物： 其药学上可接受的盐或溶液、 其中 Y 是式中的基团： 其中环 A 是任选取代的芳基或任选取代的杂芳基，X3 是 COOR17 或类似物 Y 不是被式中的任选取代的苯基：-CR9R10X3、 R1 至 R10 各自独立地为卤素、羟基、任选取代的低级烷基、任选取代的芳基或类似物、 X1 是-O-、-S-或类似物。
• INHIBITORS OF JNK
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2576559B1

  公开（公告）日：2015-03-04
• Arylacetate Derivatives Having Isoxazole Skeleton
  申请人：Kanda Yasuhiko

  公开号：US20090062531A1

  公开（公告）日：2009-03-05

  A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X 3 is COOR 17 or the like Y is not optionally substituted phenyl which is substituted with the formula: —CR 9 R 10 X 3 at the para position, R 1 to R 10 are each independently halogen, hydroxy, optionally substituted lower alkyl, optionally substituted aryl or the like, X 1 is —O—, —S— or the like.